This morning, the American Civil Liberties Union, which will be represented in Wednesday’s hearing on Section 101 reform by Senior Legislative Counsel Kate Ruane, announced an urgent joint phone briefing for members of Congress and staff to address the contention that the “Proposed Patent Bill Would Jeopardize Health Care and Harm Medical Research.” The phone briefing, taking place today at 2:30 pm EST, will be jointly held by representatives from the ACLU, the Association for Molecular Pathology, a breast cancer survivor and patient, My Gene Counsel, and Invitae. Below, Sherry Knowles, former Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, rebuts the arguments made in both the ACLU’s briefing announcement and associated letter to Congress on this topic.
Recent Posts
- IP News: Barks & Bites for Friday, March 14 | IPWatchdog
- CAFC: Prior Art Requires Written Support for Jepson Claim
- The Return of a Mandate on Patent Infringement Precludes Further Consideration of Issues Actually Decided
- CAFC Affirms TTAB Ruling that FIREBALL is Not Generic but Competitor’s Mark Won’t Confuse
- John Squires Becomes Official Nominee to Head USPTO